NPI: 1912399601 · POCAHONTAS, AR 72455 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/04/2015
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 03/04/2015 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 1,195 | $23K |
| 2019 | 4,906 | $66K |
| 2020 | 2,843 | $74K |
| 2021 | 2,799 | $49K |
| 2022 | 638 | $15K |
| 2023 | 2,203 | $55K |
| 2024 | 24 | $1K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 10,148 | 682 | $221K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 3,122 | 184 | $40K |
| 82728 | 122 | 76 | $7K | |
| 83540 | 141 | 88 | $4K | |
| 83970 | 109 | 75 | $3K | |
| 82108 | 28 | 12 | $3K | |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 83 | 50 | $2K |
| 83550 | 114 | 63 | $2K | |
| A4657 | Syringe, with or without needle, each | 247 | 191 | $2K |
| 85041 | 120 | 77 | $24.46 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 81 | 49 | $0.00 |
| 85048 | 123 | 76 | $0.00 | |
| 85045 | 28 | 25 | $0.00 | |
| J1756 | Injection, iron sucrose, 1 mg | 142 | 37 | $0.00 |